BiotechTube
Adoram Therapeutics

Adoram Therapeutics

Basel, Switzerland· Est.
adoram.ch
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4M

Overview

Adoram Therapeutics is a preclinical-stage biotech company developing allosteric small molecule drugs targeting G-protein-coupled receptors (GPCRs), with a primary focus on immuno-oncology and inflammation. Its lead asset is an A2AR NAM for solid tumors, demonstrating promising preclinical data and nearing clinical candidate stage. The company possesses a proprietary allosteric screening technology and a licensed portfolio, aiming to build a multi-asset pipeline through internal R&D and strategic partnerships.

OncologyImmunologyInflammatory Diseases

Technology Platform

Proprietary allosteric drug screening platform for GPCR targets, more sensitive than standard assays, coupled with virtual compound libraries and specialized know-how in allosteric biochemistry.

Funding History

1
Total raised:$4M
Seed$4M

Opportunities

The large, growing immuno-oncology market has a clear need for novel, orally available small molecule immunotherapies to complement or improve upon existing biologics.
Adoram's allosteric approach offers a potential best-in-class safety and efficacy profile that could command premium partnership deals.
The adaptable platform also allows for rapid expansion into other high-value GPCR targets beyond adenosine receptors.

Risk Factors

High preclinical failure risk as data must translate to human trials.
Intense competition in the A2AR antagonist space from well-funded companies poses a significant market challenge.
The company's early stage and reliance on external funding create financial and operational execution risks.

Competitive Landscape

The A2AR antagonist space is competitive, with several orthosteric small molecules and antibodies in clinical development from companies like AstraZeneca, iTeos Therapeutics, and Corvus Pharmaceuticals. Adoram's key differentiation is its allosteric mechanism, which aims for greater selectivity and a superior safety window. However, it must prove this advantage clinically against more advanced competitors.

More companies in Small Molecule Drugs →More companies in Switzerland →